Edgewise Therapeutics (EWTX) Stock Forecast: StockMap's 2-Week Call
EWTX stock forecast: StockMap's model makes no two-week call on Edgewise Therapeutics after the Nov 19 close: its evidence is split, 6 reasons for and 9 against. Too few two-week windows graded to judge yet.
Edgewise Therapeutics last closed at $41.17, -0.48% on the session.
Against the IVW growth benchmark the position is +1.85% over the forecast window.
Edgewise Therapeutics' market cap is $4.51B as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -6 (too close to call).
Where EWTX sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 6 bullish and 9 bearish.
Agreement across those insights is 60%.
3 daily calls for EWTX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Edgewise Therapeutics in the 95th percentile on valuation and the 97th percentile on return on equity, where 100 is best.
Edgewise Therapeutics is classified under Health Care / Pharmaceuticals.
StockMap tracks Edgewise Therapeutics as the 29th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite Edgewise Therapeutics ranks 23rd of 153 in the group, against a group median of -0.36.